Indirect comparison of different adjuvant chemotherapies for stage II-III gastric cancer after D2 gastrectomy in Asian patients / 中华胃肠外科杂志

<p><b>OBJECTIVE</b>To compare efficacy of different adjuvant chemotherapy regimens for stage II-III gastric cancer after D2 gastrectomy in Asian patients.</p><p><b>METHODS</b>Associated literatures were searched through electronic databases and hand-searching. Prospective randomized clinical trials (RCTs) comparing adjuvant chemotherapy after D2 gastrectomy with surgery alone were included in the study. Overall survival and disease-free survival were chosen as the endpoints. Relative hazard was analyzed by Bucher adjusted indirect comparison.</p><p><b>RESULTS</b>Two RCTs were selected, including comparison between S-1 versus surgery alone and comparison between XELOX versus surgery alone. There was no statistical difference in overall survival between the two regimens (HR=0.94, 95%CI:0.62-1.44, P=0.79). The recurrence risk of S-1 was slightly higher as compared to XELOX, but no statistical difference was found (HR=1.11, 95%CI:0.80-1.53, P=0.54).</p><p><b>CONCLUSION</b>The adjuvant chemotherapy with S-1 is similar to XELOX for stage II-III gastric cancer after D2 gastrectomy in Asian patients.</p>

Prognostic factor analysis of 116 cases of primary gastrointestinal non-Hodgkin's lymphoma / 南方医科大学学报

<p><b>OBJECTIVE</b>To investigate the factors that affect the prognosis of primary gastrointestinal non-Hodgkin's lymphoma (PGI-NHL).</p><p><b>METHODS</b>The clinical data of 116 patients with pathologically confirmed PGI-NHL we treated from January 1993 to December 2003 were analyzed retrospectively. Kaplan-Meier survival analysis was used for analyzing the survival of the patients, and Log-rank test was performed to compare the survival rates in relation to different prognostic factors.</p><p><b>RESULTS</b>The 3-year and 5-year survival rates of the patients were 63.8% (74/116) and 48.2% (40/83), respectively. Univariate analysis revealed that the factors affecting the prognosis of the patients included the presence of B symptom, tumor size, clinical stage, pathological type, depth of invasion, and treatment methods. The patients with B symptom, tumor size no less than 10 cm, advanced clinical stage (stages III(E) and IV(E)), T-cell type, and invasion beyond the serosa who received only surgical management had poorer prognosis than those free of B symptom with tumor size <10 cm, early clinical stage (stages I(E) and II(E)), B-cell type, and submucosal or serosal invasion managed with chemotherapy alone or in combination with surgery. Multivariate analysis showed that B symptom, tumor size no less than 10 cm, advanced clinical stage (stages III(E) and IV(E)), T-cell type, invasion beyond the serosa, and surgery alone were independently associated with poor prognosis.</p><p><b>CONCLUSION</b>The tumor size, clinical stage, pathological type, treatment methods are the independent factors affecting the prognosis of patients with PGI-NHL.</p>

Postoperative abdominal endogenic field hyperthermia combined with FOLFOX regimen in the treatment of 68 cases of advanced gastric cancer / 南方医科大学学报

<p><b>OBJECTIVE</b>To assess the therapeutic efficacy and adverse effects of endogenetic field hyperthermia (EFH) in combination with L-OHP /LV / 5-FU in the treatment of advanced gastric cancer.</p><p><b>METHODS</b>This study included 147 surgical patients with stage II-IV gastric cancer, who received postoperative chemotherapy with FOLFOX (L-OHP 85 mg /m square, 3 h intravenous infusion, followed by infusion of LV at 200 mg /m square in 2 h, intravenous injection of 5-Fu at 400 mg /m square, and intravenous infusion of 5-FU at 3000 mg /m square in 48 h). Eight treatment cycles (each lasting for 14 days) were administered. In 68 cases randomly selected from the cohort, EFH was performed on the first and third days (treatment group), but not in the other 79 cases (control group).</p><p><b>RESULTS</b>The response rate was 68.4% in the treatment group and 36.4% in the control group, showing significant difference between them (P<0.05). The 1-year survival rate was 88.2% in the treatment group, similar to the rate of 81.0% in the control group (P< 0.05), but the 3, 5-year survival rates in treatment group (67.6% and 30.9%) was significantly higher than those in the control group (47.6% and 15.4%, P<0.05). The adverse effects were similar between the two groups.</p><p><b>CONCLUSION</b>EFH combined with the chemotherapeutic regimen FOLFOX might improve the therapeutic effect of stage II-IV gastric cancer without obviously increasing the adverse effects.</p>

Significance of expression of extracellular matrix metalloproteinase inducer in pancreatic cancer / 中华消化杂志

Objective To investigate the expression of extracellular matrix metalloproteinase inducer (EMMPRIN) in pancreatic cancer and its relationship with P-glycoprotein (P-gp) and vascular endothelial growth factor (VEGF),and to study its correlation with invasion,metastasis and drug re- sistance.Methods The expressions of EMMPRIN,P-gp and VEGF in 34 cases of pancreatic cancer were detected by immunohistochemistry.The correlation analysis and Chi squared test were been used by SPSS 10.0.Results The positive rates of EMMPRIN,P-gp and VEGF in pancreatic cancer were 61.8%,55.9% and 64.7% respectively.EMMPRIN,P-gp and VEGF were associated with lymph node metastasis (P＜0.05),but not associated with sex,age,size of tumor and degree of differentia- tion (P＞0.05).There were close relationship between EMMPR1N and P-gp,VEGF respectively (r= 0.398,r=0.432,P＜0.05).Conclusions EMMPRIN,P-gp and VEGF were higher expressed in pancreatic cancer.EMMPRIN express was correlated with both P-gp and VEGF.It has indicated that during the progression of pancreatic cancer,there are close relationship between invasion,metastasis and drug resistance,and EMMPRIN may play key role in this process.